The estimated Net Worth of Asaf Danziger is at least $76.5 million dollars as of 5 January 2023. Mr. Danziger owns over 212,500 units of NovoCure Ltd stock worth over $3,464,660 and over the last 9 years he sold NVCR stock worth over $65,732,262. In addition, he makes $7,316,610 as President, Chief Executive Officer et Director at NovoCure Ltd.
Asaf has made over 51 trades of the NovoCure Ltd stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 212,500 units of NVCR stock worth $1,627,750 on 5 January 2023.
The largest trade he's ever made was exercising 354,780 units of NovoCure Ltd stock on 14 July 2017 worth over $134,816. On average, Asaf trades about 68,279 units every 34 days since 2015. As of 5 January 2023 he still owns at least 201,083 units of NovoCure Ltd stock.
You can see the complete history of Mr. Danziger stock trades at the bottom of the page.
Asaf Danziger serves as President, Chief Executive Officer, Director of the Company. He has served as our Chief Executive Officer since 2002 and has been a director of NovoCure since 2012. From 1998 to 2002, Mr. Danziger was CEO of Cybro Medical, a subsidiary of Imagyn Medical Technologies, Inc. Mr. Danziger holds a B.Sc. in material engineering from Ben Gurion University of the Negev, Israel.
As the President, Chief Executive Officer et Director of NovoCure Ltd, the total compensation of Asaf Danziger at NovoCure Ltd is $7,316,610. There are 1 executives at NovoCure Ltd getting paid more, with William Doyle having the highest compensation of $8,286,100.
Asaf Danziger is 53, he's been the President, Chief Executive Officer et Director of NovoCure Ltd since 2012. There are 18 older and 6 younger executives at NovoCure Ltd. The oldest executive at NovoCure Ltd is Prof. Yoram Palti, 83, who is the Founder & CTO.
Asaf's mailing address filed with the SEC is C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE, PA, 19087.
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ... et Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: